Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYPA/CYPA agents: patients who are currently receiving drugs that are strong and moderate inducers or inhibitors of CYPA or CYPA are not eligible; strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYPA agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYPA are not eligible; Note: CYPA inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYPC agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYPC are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYPA agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYPA are not eligible; strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study\r\n** Note: CYPA inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible
Subjects who are currently receiving any other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until  hours prior to start of protocol therapy)
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving anti-platelet agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agents
Concomitant medications\r\n* Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anticonvulsants: Patients who are receiving enzyme-inducing anticonvulsants are not eligible\r\n* Anticoagulants: Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within  days of enrollment\r\n* Smoking: Patients must not smoke for  days prior to enrollment and for the duration of therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYPA agents: Patients who are currently receiving drugs that are strong inducers or inhibitors of CYPA are not eligible; strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study; Note: CYPA inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; corticosteroids must be held for  hours prior to initiation of study therapy\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible; the definition of investigational for use in this protocol means any drug that is not licensed by the Food and Drug Administration (FDA)\r\n* Anti-cancer agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible (except leukemia patients who relapsed on maintenance therapy or patients receiving hydroxyurea, which may be continued until  hours prior to start of protocol therapy); intrathecal therapy may be given up to one week prior to initiation of study treatment\r\n* Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least  half-lives must have elapsed after the last dose of GVHD meds\r\n* Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus + ACE inhibitors; at least  half-lives must have elapsed after the last dose of ACE inhibitors\r\n* Anti-convulsants: Patients who are currently receiving CYPA/PgP enzyme inducing anticonvulsants (eg. phenytoin, phenobarbitol, or carbamazepine) are not eligible; stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable; at least  half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants\r\n* Inhibitors of everolimus metabolism: Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of everolimus metabolism; at least  half-lives must have elapsed after the last dose of azoles
Concomitant Medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* CYPA active agents: Patients must not be receiving any of the following potent CYPA inducers or inhibitors (erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. Johns wort)\r\n* Patients who are receiving systemic therapeutic treatment anticoagulation are not eligible; patients receiving prophylactic systemic anticoagulation will be allowed with heparin or low-molecular-weight heparin (LMWH) as long as eligibility PT/INR requirements are met; concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg. clopidogrel) are not allowed\r\n* Enzyme-inducing anticonvulsants: Patients must not have received enzymeinducing anticonvulsants within  days prior to enrollment \r\n* QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible
Patients who are currently receiving other anti-cancer/devices agents are NOT eligible for either Stratum
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYPA agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYPA are not eligible; strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study\r\n* CYPC agents: patients who are currently receiving drugs that are strong CYPC inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible.
Patients must not be currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents with the exception of those delineated in the eligibility criteria
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until  hours prior to start of protocol therapy); patients with acute lymphoblastic leukemia may receive intrathecal therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents, with the exception of hydroxyurea for patients with ALCL, are not eligible
Concomitant medications:\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the  days prior to enrollment ( days if pegfilgrastim)\r\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the  days prior to enrollment are not eligible\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Patients who are currently receiving the enzyme inducing anticonvulsants: phenytoin, phenobarbital, carbamazepine, oxcarbazepine are not eligible; patients who are currently taking rifampin, voriconazole, itraconazole, ketoconazole, aprepitant, or St. Johns Wort are not eligible\r\n* Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within  days of starting protocol therapy\r\n* Patients receiving medications that prolong the QTc
Concomitant medications\r\n* Patients receiving stable or decreasing corticosteroids are not eligible for other concurrent conditions (e.g. asthma, autoimmune diseases, rash, documented adrenal insufficiency) are eligible for this study\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible
Currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are excluded from this trial
Patients who are currently receiving other anti-cancer agents are not eligible
Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
Patients who are currently receiving other anti-cancer agents are not eligible except for hydroxyurea (which may be continued until  hours prior to start of protocol therapy)
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from hematological and bone marrow suppression effects of prior chemotherapy.
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Patients who are currently receiving other anticancer agents are not eligible. Patients must have fully recovered from the effects of prior chemotherapy, generally at least  weeks from the most recent administration ( weeks for nitrosoureas).
Patients must not currently be using other anti-cancer agent
